Investigating new medications for cannabis use disorder.
Dual Fatty Acid Amide Hydrolase (FAAH)/Monoacylglycerol lipase (MAGL) Inhibitors for Cannabis Use Disorder (CUD).
['FUNDING_SBIR_1'] · MAKSCIENTIFIC, LLC · NIH-11264494
This study is looking for new medications to help people with cannabis use disorder by boosting the natural chemicals in the brain that can ease withdrawal symptoms and cravings, and it may involve patients trying out these new treatments to see how well they work and if they're safe.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAKSCIENTIFIC, LLC (nih funded) |
| Locations | 1 site (BURLINGTON, UNITED STATES) |
| Trial ID | NIH-11264494 on ClinicalTrials.gov |
What this research studies
This research focuses on developing new medications for cannabis use disorder (CUD) by targeting specific enzymes that break down endocannabinoids in the brain. The approach involves inhibiting fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) to increase levels of natural compounds that may help alleviate withdrawal symptoms and cravings associated with cannabis use. By enhancing the body's own endocannabinoid system, the research aims to provide a safer alternative to current treatments that can have unwanted side effects. Patients may be involved in trials to assess the effectiveness and safety of these new medications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals struggling with cannabis use disorder who are seeking treatment options.
Not a fit: Patients who do not have cannabis use disorder or those who are not interested in pharmacological treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective medications that help individuals overcome cannabis use disorder with fewer side effects.
How similar studies have performed: Previous research has shown promise in using similar approaches to enhance endocannabinoid activity, indicating potential for success in this area.
Where this research is happening
BURLINGTON, UNITED STATES
- MAKSCIENTIFIC, LLC — BURLINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ALAPAFUJA, SHAKIRU OLAJIRE — MAKSCIENTIFIC, LLC
- Study coordinator: ALAPAFUJA, SHAKIRU OLAJIRE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.